STOCK TITAN

Crinetics Pharmaceuticals: Driehaus reports 0% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. (CRNX) is the issuer whose common stock is covered by Driehaus Capital Management LLC’s Schedule 13G/A amendment. Driehaus reported zero beneficially owned shares and stated it had ceased being a beneficial owner.

Beneficially owned shares 0 shares Driehaus Capital Management LLC reported this amount for Crinetics common stock.
Ownership of class 0% Driehaus Capital Management LLC reported this percentage.
Voting power 0 sole; 0 shared Driehaus Capital Management LLC reported no sole or shared voting power.
Dispositive power 0 sole; 0 shared Driehaus Capital Management LLC reported no sole or shared dispositive power.
beneficial owner regulatory
"ceased being a beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRNX shares did Driehaus Capital Management report owning?

Driehaus Capital Management LLC reported 0 beneficially owned shares of Crinetics Pharmaceuticals common stock, or 0% of the class.

Did Driehaus report voting or dispositive power over CRNX shares?

Driehaus reported 0 sole and 0 shared voting power, and 0 sole and 0 shared dispositive power over the common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





22663K107

(CUSIP Number)
08/25/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, Driehaus Capital Management LLC has ceased being a beneficial owner of Crinetics Pharmaceuticals, Inc.


SCHEDULE 13G



DRIEHAUS CAPITAL MANAGEMENT LLC
Signature:Janet McWilliams
Name/Title:General Counsel
Date:11/16/2026

Keep reading